Establishment Labs Q3 2026: Revenue Climbs, Loss Narrows, and Guidance Clears the Way for 2027

Establishment Labs Holdings Inc. (NASDAQ: ESTA) delivered its third-quarter 2026 results with a revenue jump and a continued negative EPS but improved relative performance versus the prior year. The quarter closed with total revenue of $72.0 million, up 33.9% year over year. US revenue surged 119.0% to $26.0 million, while international sales (OUS) rose 9.7% to $46.0 million. The minimally invasive segment contributed approximately $9 million in revenue, underscoring a diversified mix as the company leans into its core Motiva platform.

On the profitability line, GAAP gross profit was $49.7 million, or 69.1% of revenue, down slightly from 70.1% a year ago — a reminder that gross margin is a moving target in device manufacturing, even as volumes rise. Inventory charges of about $1.3 million were disclosed as part of restructuring efforts, which nudged adjusted gross margin to about 70.8% when excluded. GAAP operating expenses ran $52.3 million; adjusted operating expenses, which exclude litigation- and restructuring-related costs, were $49.6 million (68.8% of revenue).

The company reported a GAAP net loss of $10.7 million, or $(0.35) per share, narrowing from the prior-year loss. Adjusted EBITDA came in at $6.4 million, or 8.9% of revenue, versus $1.2 million (2.2% of revenue) a year earlier. In other words, the business is generating more cash at the top end, even as the bottom line still carries a loss on a GAAP basis.

Third Quarter Highlights and strategic moves

• Announced a new supply agreement with NuSil to support long-term manufacturing capacity and future growth.
• FDA approval for additional smaller Motiva implant sizes, expanding options for U.S. surgeons and patients.
• Launched larger implant sizes for the minimally invasive platform, broadening treatment options and potential patient population.
• Expanded the U.S. commercial footprint to more than 2,100 accounts, with over 400 plastic surgeons trained on Preservé.
• FDA review of Motiva for breast reconstruction progressing in line with expectations.

Guidance and forward-looking implications

The release emphasizes that the quarter underpins a broader push toward profitability, with the company “raising full-year revenue guidance.” Investors should note that this implies a stronger revenue forecast for the remainder of 2026, even as the reported EPS remains negative on a GAAP basis. The narrative around forward performance hinges on several moving parts: the US sales engine’s scale, the contribution of the minimally invasive platform, and continued progress in regulatory and manufacturing capacity. In the language investors use to parse earnings, this is the kind of quarter where earnings surprise risk is more about whether management can sustain the top-line momentum and convert it into operating leverage than about a one-quarter beat on the headline number.

Analysts watching ESTA will likely weigh the negative GAAP EPS against the improving cash flow profile and the margin discipline evident in the adjusted figures. The absence of a disclosed EPS consensus in the release means the street’s EPS consensus may not yet be fully aligned with the company’s new guidance; the market will scrutinize whether the mix shift toward higher-margin US sales and the new supply arrangements can lift profitability in the near term.

What this portends for ESTA and its peers

ESTA’s quarter, anchored by a robust top line and a strategy to expand capacity and product breadth, signals a potentially durable growth story in breast aesthetics and reconstruction. The NuSil supply agreement and the FDA opt‑in for more Motiva sizes suggest the company is methodically stacking structural levers—supply resilience, regulatory clearance, and product breadth—rather than chasing near-term price or volume gimmicks.

For sector peers, the takeaway is twofold: first, the importance of a scalable U.S. commercial footprint remains critical for premium-angled devices; second, the ability to translate top-line growth into improved cash flow increasingly matters to justify valuation in a capex-heavy, R&D-intensive segment. The “earnings surprise” calculus in this space now leans more toward trajectory and program execution than quarterly beats, a shift that benefit-following investors may reward with multiple expansion if the path toward profitability proves durable.

Bottom line

Establishment Labs’ Q3 2026 results reflect a company executing on growth while bending toward cash flow generation. Revenue growth is tangible, the product portfolio broadens, and the cost structure shows signs of leverage as the mix shifts toward higher-margin US sales. The negative EPS remains a hurdle, but a stronger revenue forecast and positive free cash flow conversations could catalyze a re-rating if the trajectory holds. For investors and peers, ESTA’s performance reinforces a theme: in specialized medical devices, clinical-grade growth—backed by supply resilience, regulatory progress, and thoughtful product expansion—can outpace headline profitability in the near term while laying a foundation for a more durable earnings narrative in 2027.

Bonus Matt Levine aside: if you’re measuring the quarter in the language of lab coats, this is less a dramatic breakthrough and more a steady calibration—the needle is moving, the chart is pointing up, and the beaker is finally getting less hot. The real test is whether the new guidance sticks to the hairline crack of a positive operating and free cash flow quarter, or whether the burn rate returns to form as the annual price of growth accrues.